If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.25    0.00 (0.00%)
Bid:
8.00
Ask:
8.50
Spread: 0.50 (6.25%)
Market Cap: £18.07m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Annual Information Update

6 Feb 2012 09:25

RNS Number : 8480W
Phytopharm PLC
06 February 2012
 

Phytopharm plc

 

Annual Information Update

Phytopharm plc (the Company) announces that, in accordance with the requirements of Prospectus Rule 5.2 issued by the Financial Services Authority, and following publication of the Annual Report on 6 February 2012, the following information has been published or made available to the public between 8 February 2011 and 6 February 2012 inclusive, in compliance with laws and rules dealing with the regulation of securities, issuers of securities and securities markets.

1. Announcements made via the Regulatory Information Service ("RIS")

All the announcements listed below were published through a regulatory information service on the dates indicated. Copies can be obtained from the London Stock Exchange website, http://www.londonstockexchange.com or from the Company's website www.phytopharm.com

Date of publication

Title

2 February 2012

Appointment of Non-Executive Director

27 January 2012

Publication of 2011 annual report

16 January 2012

Research update

11 January 2012

Block listing cancellation

3 January 2012

Block listing interim review

28 November 2011

Director/PDMR shareholding

28 November 2011

Director/PDMR shareholding

24 November 2011

Final results

8 November 2011

Notice of results

7 November 2011

Block listing interim review

4 October 2011

Research update

29 September 2011

Research update

16 August 2011

Interim management statement

28 July 2011

Research update

12 July 2011

Block listing interim review

5 July 2011

Total voting rights

17 June 2011

Block listing interim review

26 May 2011

Half yearly report

17 May 2011

Notice of results

5 May 2011

Block listing interim review

31 March 2011

Results of AGM

2 March 2011

Holding(s) in Company

15 February 2011

Interim management statement

7 February 2011

Annual information update

2. Documents published or sent to Shareholders or submitted to the FSA including those filed with the National Storage Mechanism:

Date of publication

Title

27 January 2012

Annual Report 2011

26 May 2011

Interim Report 2011

30 March 2011

AGM resolutions 2011

The 2011 Interim and 2011 Annual reports are available on the Company's website www.phytopharm.com

3. Documents filed at Companies House

The following documents were files at Companies House. Copies of these documents can be obtained from the Companies House website at www.companieshouse.gov.uk, or Companies House, Crown Way, Cardiff CF14 3UZ

Date of Publication

Title

2 January 2012

Form AP01 Appointment of Director

27 January 2012

Annual Report 2011

15 December 2011

Form AR01 Annual return

5 December 2011

Form AD02 Single alternative inspection location

6 June 2011

Form AH01 Return of allotment of shares on 6 June 2011

31 March 2011

AGM resolutions

Copies of all documents referred to above are also available for inspection at the Company's registered office (Lakeview House, 2 Lakeview Court, Ermine Business Park, Huntingdon, Cambridgeshire PE29 6UA, United Kingdom) during normal business hours or by written request from the Company Secretary.

This annual information is required by, and is being made pursuant to, Article 10 of the Prospectus Directive as implemented by the UK Prospectus Rule 5.2 and not for any other purpose and neither the Company, nor any other person, takes any responsibility for, or makes any representation, express of implied, as to the accuracy or completeness of, the information which it contains. The information is not necessarily up to date as at the date of this annual information update and the Company does not undertake any obligation to update any such information in the future. Neither this annual information update, not referred to in it, constitutes, by virtue of this communication, an offer of securities addressed to any person and it should not be relied on by any person.

For further information, please contact:

Zoe McGowan, Company Secretary

Phytopharm plc Tel No: +44 (0)1480 437697

Further information about Phytopharm can be found on the Company's website www.phytopharm.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AIUEANAKEAAAEEF
Date   Source Headline
11th Jun 202111:35 amRNSHolding(s) in Company
25th May 20217:00 amRNSHalf yearly report to 31 March 2021
20th May 20217:00 amRNSPhase II Alzheimer’s disease contract award
19th May 20217:00 amRNSContract win for new neuroinflammatory disorder
11th May 20217:00 amRNSNotice of results
28th Apr 20217:00 amRNSContract win for new stroke study
26th Apr 20217:00 amRNSTrading update
19th Apr 20218:21 amRNSHolding(s) in Company
12th Apr 20214:00 pmRNSHolding(s) in Company
12th Apr 20217:00 amRNSInvestment in Ixico plc
1st Apr 20217:00 amRNSHolding(s) in Company
25th Mar 20219:14 amRNSPDMR Transaction
24th Mar 20219:05 amRNSSecond Price Monitoring Extn
24th Mar 20219:00 amRNSPrice Monitoring Extension
23rd Mar 20214:40 pmRNSSecond Price Monitoring Extn
23rd Mar 20214:35 pmRNSPrice Monitoring Extension
23rd Mar 20213:05 pmRNSHuntington’s disease Phase III contract updates
15th Mar 20214:41 pmRNSSecond Price Monitoring Extn
15th Mar 20214:35 pmRNSPrice Monitoring Extension
15th Mar 20212:06 pmRNSSecond Price Monitoring Extn
15th Mar 20212:00 pmRNSPrice Monitoring Extension
15th Mar 202111:06 amRNSSecond Price Monitoring Extn
15th Mar 202111:01 amRNSPrice Monitoring Extension
15th Mar 20217:00 amRNSCollaboration with Microsoft
10th Mar 20217:00 amRNSIXICO chosen for new Phase II AD study
2nd Mar 20217:00 amRNSIXICO selected by Cyclerion for a new AD study
1st Mar 20215:25 pmRNSExercise of Options; PDMR Dealing
1st Mar 20217:00 amRNSConference attendance and presentations
29th Jan 202110:19 amRNSPDMR Dealing
21st Jan 202111:05 amRNSResult of AGM
7th Jan 20217:00 amRNSIssue of Equity
24th Dec 20207:00 amRNSIXICO secures new contract for £3.4 million
14th Dec 202011:54 amRNSHolding(s) in Company
8th Dec 20207:00 amRNSIXICO contract with new large global pharma
3rd Dec 20202:06 pmRNSSecond Price Monitoring Extn
3rd Dec 20202:01 pmRNSPrice Monitoring Extension
2nd Dec 20207:00 amRNSFinancial Results for the year ended 30 Sept 2020
27th Nov 20207:00 amRNSIXICO announces £1.9 million new study award
9th Nov 20207:00 amRNSNotice of Results
3rd Nov 20207:00 amRNSAdditional Alzheimer’s disease contracts
22nd Oct 20207:00 amRNSFurther Huntington’s disease contracts
19th Oct 20207:00 amRNSIXICO to Present at SCA & ARCA Global Conference
19th Oct 20207:00 amRNSTrading Update for year ended 30 September 2020
16th Oct 20207:00 amRNSIXICO and NYU Langone Health sign agreement
30th Sep 20202:05 pmRNSSecond Price Monitoring Extn
30th Sep 20202:00 pmRNSPrice Monitoring Extension
29th Sep 20207:00 amRNS>£2m contract extension win - Huntington’s disease
24th Sep 20207:00 amRNSCollaboration with TRACK-FA NeuroimagingConsortium
21st Sep 20207:00 amRNSIXICO selected to support Alzheimer’s trial
11th Sep 202010:36 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.